$0.10
+0.01 (+13.70%)
Open$0.10
Previous Close$0.09
Day High$0.11
Day Low$0.09
52W High$4.55
52W Low$0.08
Volume—
Avg Volume15.63M
Market Cap5.24M
P/E Ratio—
EPS$-1.22
SectorBiotechnology
Analyst Ratings
Strong Sell
9 analysts
Price Target
+40,201.2% upside
Current
$0.10
$0.10
Target
$40.14
$40.14
$31.69
$40.14 avg
$63.06
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 548.9K | 523.5K | 509.5K |
| Net Income | 128.1K | 108.5K | 123.6K |
| Profit Margin | 23.3% | 20.7% | 24.3% |
| EBITDA | 177.1K | 173.7K | 174.5K |
| Free Cash Flow | 145.7K | 139.2K | 108.0K |
| Rev Growth | +23.9% | +19.4% | -4.0% |
| Debt/Equity | 0.65 | 0.64 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |